The biotechnology firm Replimune approaches a critical juncture. On April 10, 2026, the U.S. Food and Drug Administration (FDA) is set to deliver its verdict on the approval application for RP1, a treatment for advanced melanoma. This date represents a high-stakes, binary event for the company, coming after a previous rejection and holding the power to define its immediate trajectory.
A Crucial Second Attempt
This regulatory milestone is far from routine. Replimune’s path to this point has been arduous. The company faced a significant setback in July 2025 when the FDA issued a rejection for its initial application. It wasn’t until October of that same year that Replimune was able to resubmit, initiating this second review cycle. The extended timeline has amplified investor anxiety as the decision date nears, with the outcome poised to determine the short-term fate of the enterprise.
Financial Context and Divergent Analyst Views
The company’s current market valuation of approximately $631 million underscores the prevailing uncertainty. With recent reported losses of $3.58 per share, its financial runway adds pressure, making the success of RP1 imperative. Market experts display a mix of caution and measured optimism, as reflected in their price targets:
Should investors sell immediately? Or is it worth buying Replimune?
- BMO Capital Markets: $11 price target (Market Perform rating)
- H.C. Wainwright: $12 price target (Buy rating)
- Analyst Consensus: Approximately $13 price target
The range in these assessments indicates the market is pricing in the tangible risk of another failure. While some observers have strategically adjusted their positions, bullish analysts anticipate a substantial re-rating of the stock should approval be secured.
The April 10 deadline concludes months of waiting. An FDA endorsement would pave the way for Replimune’s entry into the commercial market and validate its fundamental strategy. Conversely, a second rejection would call the future of the RP1 program and the company’s strategic direction into serious question.
Ad
Replimune Stock: Buy or Sell?! New Replimune Analysis from April 1 delivers the answer:
The latest Replimune figures speak for themselves: Urgent action needed for Replimune investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 1.
Replimune: Buy or sell? Read more here...
